AcSDKP — a new peptide treatment to help recovery after traumatic brain injury
AcSDKP as a novel treatment for traumatic brain injury
Researchers are developing a small natural peptide called AcSDKP to help people recover brain function after a traumatic brain injury.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-11289479 on NIH RePORTER |
What this research studies
This project tests a naturally occurring small peptide called AcSDKP to help the brain heal after traumatic injury. So far researchers have given AcSDKP to rats shortly after a controlled brain injury and found less brain cell loss, smaller lesions, reduced harmful fibrin buildup, and better functional recovery. They are studying how AcSDKP may reduce inflammation and alter repair pathways, including growth of blood vessels, new synapses, and new neurons. The team plans to use these findings to guide next steps toward safe human testing and potential treatments.
Who could benefit from this research
Good fit: People with a recent moderate-to-severe traumatic brain injury, especially those who could be treated soon after the injury, would be the likely candidates for future testing.
Not a fit: People with long-standing, stable brain injuries, those who already recovered from a mild concussion, or patients with medical conditions that rule out experimental therapies may not benefit.
Why it matters
Potential benefit: If successful, AcSDKP could reduce brain damage and improve recovery after TBI, potentially decreasing long-term disability and future dementia risk.
How similar studies have performed: Preclinical animal studies show promising neuroprotective and repair-promoting effects of AcSDKP, but it has not yet been tested for safety or effectiveness in people.
Where this research is happening
East Lansing, United States
- Henry Ford Health + Michigan State University Health Sciences — East Lansing, United States (Active)
Researchers
- Principal investigator: Xiong, Ye — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Xiong, Ye
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.